Vanguard Personalized Indexing Management’s Gevo GEVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$82.8K Sell
30,316
-463
-2% -$959 ﹤0.01% 1980
2025
Q4
$61.6K Buy
30,779
+1,283
+4% +$2.82K ﹤0.01% 1864
2025
Q3
$57.8K Buy
29,496
+338
+1% +$551 ﹤0.01% 1890
2025
Q2
$38.5K Sell
29,158
-1,260
-4% -$1.48K ﹤0.01% 1854
2025
Q1
$35.3K Sell
30,418
-10,300
-25% -$17.2K ﹤0.01% 1710
2024
Q4
$85.1K Buy
40,718
+4,999
+14% +$9.47K ﹤0.01% 1635
2024
Q3
$58.2K Sell
35,719
-8,011
-18% -$6.49K ﹤0.01% 1664
2024
Q2
$24.4K Buy
43,730
+28,378
+185% +$19K ﹤0.01% 1633
2024
Q1
$11.8K Buy
+15,352
New +$13.3K ﹤0.01% 1617
2023
Q4
Sell
-12,579
Closed -$15K 1593
2023
Q3
$15K Buy
12,579
+373
+3% +$551 ﹤0.01% 1468
2023
Q2
$18.6K Buy
+12,206
New +$15.8K ﹤0.01% 1450

Other funds holding GEVO

Vanguard Personalized Indexing Management's GEVO Position: Q1 2026 in Review

Vanguard Personalized Indexing Management reduced its Gevo (GEVO) stake by 1.5% in Q1 2026, selling an estimated $959 and leaving 30,316 shares worth $82.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1980.

Vanguard Personalized Indexing Management first reported a position in GEVO in Q2 2023 and has held it in 11 quarters since. The position peaked at $85.1K in Q4 2024. 161 funds tracked by Wall St. Rank hold GEVO as of Q1 2026.

  • Vanguard Personalized Indexing Management held 30,316 shares of Gevo worth $82.8K as of Q1 2026.
  • Vanguard Personalized Indexing Management sold 463 Gevo shares in Q1 2026, an estimated $959.
  • Gevo made up ﹤0.01% of Vanguard Personalized Indexing Management's portfolio in Q1 2026, its #1980 holding.
  • Vanguard Personalized Indexing Management first reported a position in Gevo in Q2 2023 and has held it in 11 quarters since.
  • Vanguard Personalized Indexing Management's Gevo position peaked at $85.1K in Q4 2024.
  • 161 funds tracked by Wall St. Rank held Gevo as of Q1 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q1 2026, filed 14 May 2026.